Rosalind Advisors, Inc. Top Holdings and 13F Report (2026) About Rosalind Advisors, Inc.Investment ActivityRosalind Advisors, Inc. has $248.89 million in total holdings as of March 31, 2026.Rosalind Advisors, Inc. owns shares of 38 different stocks, but just 15 companies or ETFs make up 80% of its holdings.Approximately 33.84% of the portfolio was purchased this quarter.About 36.90% of the portfolio was sold this quarter.This quarter, Rosalind Advisors, Inc. has purchased 42 new stocks and bought additional shares in 10 stocks.Rosalind Advisors, Inc. sold shares of 10 stocks and completely divested from 18 stocks this quarter.Largest Holdings Delcath Systems $30,627,610Xeris Biopharma $18,743,860Adherex Technologies $17,885,436Savara $17,492,317Vaxcyte $16,851,900 Largest New Holdings this Quarter 92243G108 - Vaxcyte $16,851,900 Holding929033207 - VOR BIOPHARMA INC $12,488,000 Holding15117B202 - Celldex Therapeutics $10,467,600 Holding09058V103 - BioCryst Pharmaceuticals $8,787,503 Holding04683R106 - Atea Pharmaceuticals $6,304,580 Holding Largest Purchases this Quarter Vaxcyte 290,000 shares (about $16.85M)VOR BIOPHARMA INC 700,000 shares (about $12.49M)Celldex Therapeutics 330,000 shares (about $10.47M)BioCryst Pharmaceuticals 923,057 shares (about $8.79M)Xeris Biopharma 1,120,000 shares (about $6.50M) Largest Sales this Quarter CG ONCOLOGY INC 200,000 shares (about $13.54M)Viridian Therapeutics 199,599 shares (about $3.90M)SPDR S&P 500 ETF TR 385,000 shares (about $2.95M)Profound Medical 240,837 shares (about $1.56M)ONKURE THERAPEUTICS INC 286,725 shares (about $1.19M) Sector Allocation Over TimeMap of 500 Largest Holdings ofRosalind Advisors, Inc. Selling Neutral Buying Latest 13F Holdings and Changes Since Previous Quarterly FilingIssuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSectorDCTHDelcath Systems$30,627,6100.0%3,300,38912.3%MedicalXERSXeris Biopharma$18,743,860$6,496,000 â–²53.0%3,231,7007.5%MedicalFENCAdherex Technologies$17,885,436$1,812,362 â–²11.3%2,908,2017.2%MedicalSVRASavara$17,492,317$1,092,000 â–¼-5.9%3,203,7217.0%MedicalPCVXVaxcyte$16,851,900$16,851,900 â–²New Holding290,0006.8%MedicalEYPTEyepoint Pharmaceuticals$13,363,540$4,469,440 â–²50.3%1,036,7375.4%MedicalX4 PHARMACEUTICALS INC$13,276,984$2,514,534 â–²23.4%3,214,7665.3%COM NEWVOR BIOPHARMA INC$12,488,000$12,488,000 â–²New Holding700,0005.0%COM NEWMDWDMediWound$12,067,2600.0%749,0544.8%MedicalVSTMVerastem$11,333,918$1,855,000 â–²19.6%2,138,4754.6%MedicalCLDXCelldex Therapeutics$10,467,600$10,467,600 â–²New Holding330,0004.2%MedicalBCRXBioCryst Pharmaceuticals$8,787,503$8,787,503 â–²New Holding923,0573.5%MedicalCYBIN INC$7,352,707$603,485 â–¼-7.6%1,531,8143.0%COM NEWCG ONCOLOGY INC$6,768,000$13,536,000 â–¼-66.7%100,0002.7%COMNSPRInspireMD$6,366,3610.0%3,905,7432.6%MedicalAVIRAtea Pharmaceuticals$6,304,580$6,304,580 â–²New Holding1,171,8552.5%MedicalPROFProfound Medical$5,366,205$1,560,624 â–¼-22.5%828,1182.2%MedicalVRDNViridian Therapeutics$4,897,844$3,904,157 â–¼-44.4%250,4012.0%MedicalREPLIMUNE GROUP INC$2,746,725$2,249,532 â–²452.4%1,275,6001.1%CALLPOLYPID LTD$2,618,916$431,999 â–¼-14.2%597,9261.1%COMMYOMyomo$2,599,217$5,067 â–²0.2%3,847,2721.0%MedicalTALPHERA INC$2,505,040$168,319 â–¼-6.3%3,353,9161.0%COM NEWOVIDOvid Therapeutics$2,459,747$2,459,747 â–²New Holding1,107,9941.0%MedicalDEFINIUM THERAPEUTICS INC$2,362,500$2,362,500 â–²New Holding125,0000.9%COM SHSONKURE THERAPEUTICS INC$1,837,179$1,187,042 â–¼-39.3%443,7630.7%COM CL ALPCNLipocine$1,770,712$1,770,712 â–²New Holding221,6160.7%MedicalNEURAXIS INC$1,693,9370.0%286,1380.7%COMAVALO THERAPEUTICS INC$1,119,750$1,119,750 â–²New Holding75,0000.4%COM NEWANNXAnnexon$1,108,000$1,108,000 â–²New Holding200,0000.4%MedicalINVESCO QQQ TR$1,053,000$842,400 â–¼-44.4%250,0000.4%PUTAQSTAquestive Therapeutics$1,037,500$1,037,500 â–²New Holding250,0000.4%MedicalSPDR S&P 500 ETF TR$958,500$2,952,180 â–¼-75.5%125,0000.4%PUTBIOFRONTERA INC$941,645$18,767 â–²2.0%1,163,9620.4%COM NEWKURAKura Oncology$813,0000.0%100,0000.3%MedicalREGENTIS BIOMATERIALS LTD$768,3630.0%251,5100.3%ORDINARY SHARESVIRIDIAN THERAPEUTICS INC$52,720$52,720 â–²New Holding263,6000.0%PUTUNIQURE NV$0195.8%295,8000.0%CALLARRIVENT BIOPHARMA INC$00.9%108,9000.0%CALLREPLReplimune Group$0$13,710,031 â–¼-100.0%00.0%MedicalLIFEEthos Technologies Inc. Class A Common Stock$0$13,601,557 â–¼-100.0%00.0%CYTKCytokinetics$0$12,393,159 â–¼-100.0%00.0%MedicalMNMDMind Medicine (MindMed)$0$10,042,500 â–¼-100.0%00.0%MedicalOCULOcular Therapeutix$0$4,856,000 â–¼-100.0%00.0%MedicalARRIVENT BIOPHARMA INC$0$4,343,325 â–¼-100.0%00.0%COMANAVEX LIFE SCIENCES CORP$0$1,880,860 â–¼-100.0%00.0%PUTSPDR SERIES TRUST$0$1,347,600 â–¼-100.0%00.0%PUTTRVITrevi Therapeutics$0$1,252,000 â–¼-100.0%00.0%MedicalISHARES TR$0$1,112,000 â–¼-100.0%00.0%PUTFRACTYL HEALTH INC$0$848,608 â–¼-100.0%00.0%COMVERASTEM INC$0$159,810 â–¼-100.0%00.0%CALLVIKING THERAPEUTICS INC$0$2,000 â–¼-100.0%00.0%CALLVISTAGEN THERAPEUTICS INC$0-100.0%00.0%CALLREPLIMUNE GROUP INC$0-100.0%00.0%PUTREZOLUTE INC$0-100.0%00.0%CALLShowing largest 100 holdings. View all holdings. More Institutional Buying and Selling Information SEC Filings and Trading Data SEC Filings 13F Filings Top 13F Buys Top 13F Sells Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
